Intrinsic Value
Lyell Immunopharma, Inc. · LYEL
Conservative
More adverse but historically defensible assumptions.
-$3.02
Base
The model's central intrinsic-value estimate.
-$5.27
Optimistic
More favorable but historically defensible assumptions.
-$10.65
Scenarios are the same model run under different but historically defensible assumptions. They are not price targets. Where a valuation gap is shown it is a comparison with a recent close, not a forecast return; where the price is stale, no gap is shown at all.
Model confidence: 68%Valuation as of Sep 21, 2026Latest filing used Mar 12, 2026
Confidence reflects data completeness, accounting quality, and model reliability. It is not a probability of future price.
Valuation drivers
- Normalized operating margin
- -488593.8%
- Normalized NOPAT margin
- -385989.1%
- Revenue growth
- -47.0%
- WACC
- 9.20%
- Terminal growth
- 0.00%
- Reinvestment method
- direct reinvestment
- Terminal-value share
- 10.8%
Model notes (2)
- Interest-bearing debt unavailable
- Minority interest not reported
Model details
- Normalization
- V1
- Scenario
- V2
- Confidence
- V1
- Engine version
- valuation-1.0.1-share-units-terminal
- Data snapshot
- filed:2026-03-12